Craig T. Jordan

27.0k total citations · 11 hit papers
237 papers, 17.3k citations indexed

About

Craig T. Jordan is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Craig T. Jordan has authored 237 papers receiving a total of 17.3k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Hematology, 133 papers in Molecular Biology and 47 papers in Oncology. Recurrent topics in Craig T. Jordan's work include Acute Myeloid Leukemia Research (108 papers), Histone Deacetylase Inhibitors Research (42 papers) and Hematopoietic Stem Cell Transplantation (32 papers). Craig T. Jordan is often cited by papers focused on Acute Myeloid Leukemia Research (108 papers), Histone Deacetylase Inhibitors Research (42 papers) and Hematopoietic Stem Cell Transplantation (32 papers). Craig T. Jordan collaborates with scholars based in United States, Canada and United Kingdom. Craig T. Jordan's co-authors include Mónica L. Guzmán, Ihor R. Lemischka, Mark Noble, Daniel A. Pollyea, Jeffrey M. Rosen, Randall M. Rossi, Shanshan Pei, Dianna S. Howard, William Matthews and Michael W. Becker and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Craig T. Jordan

229 papers receiving 17.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer Stem Cells

2006 1.4k citations Craig T. Jordan, Mónica L. Guzmán et al. profile →
BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells

2013 943 citations Randall M. Rossi, Mohammad Minhajuddin et al. profile →
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

2000 623 citations Craig T. Jordan, Barry Grimes et al. profile →
Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells

2001 592 citations Mónica L. Guzmán, Barry Grimes et al. Blood profile →
The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells

2005 546 citations Mónica L. Guzmán, Randall M. Rossi et al. Blood profile →
The Increasing Complexity of the Cancer Stem Cell Paradigm

2009 536 citations Craig T. Jordan et al. profile →
A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations

1991 484 citations Craig T. Jordan et al. profile →
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

2018 481 citations Daniel A. Pollyea, Brett M. Stevens et al. Nature Medicine profile →
Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche

2016 395 citations Haobin Ye, Biniam Adane et al. profile →
Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells

2018 388 citations Courtney L. Jones, Brett M. Stevens et al. profile →
Acute myeloid leukaemia

2016 289 citations Ross L. Levine, Craig T. Jordan et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Craig T. Jordan United States	62	10.2k	6.6k	4.5k	3.6k	3.0k	237	17.3k
Carsten Müller‐Tidow Germany	64	11.4k 1.1×	5.3k 0.8×	4.3k 1.0×	4.3k 1.2×	2.2k 0.7×	492	18.0k
Anthony Letai United States	62	12.2k 1.2×	3.7k 0.6×	4.5k 1.0×	2.1k 0.6×	2.9k 1.0×	175	18.2k
Constantine S. Mitsiades United States	68	14.1k 1.4×	9.5k 1.4×	7.3k 1.6×	2.2k 0.6×	2.4k 0.8×	296	20.0k
Hubert Serve Germany	59	8.5k 0.8×	6.8k 1.0×	3.1k 0.7×	2.9k 0.8×	1.7k 0.6×	299	15.5k
Steven Grant United States	79	16.7k 1.6×	3.6k 0.5×	6.3k 1.4×	2.3k 0.6×	2.2k 0.7×	451	23.2k
Steven M. Kornblau United States	69	8.3k 0.8×	7.2k 1.1×	3.4k 0.7×	2.1k 0.6×	2.1k 0.7×	406	15.4k
Guido Marcucci United States	77	14.3k 1.4×	9.8k 1.5×	3.1k 0.7×	6.1k 1.7×	2.4k 0.8×	489	22.5k
Omar Abdel‐Wahab United States	68	10.9k 1.1×	7.4k 1.1×	2.2k 0.5×	3.7k 1.0×	1.9k 0.6×	306	18.6k
Irene M. Ghobrial United States	71	8.6k 0.8×	6.5k 1.0×	5.2k 1.1×	2.3k 0.6×	2.9k 1.0×	484	17.1k
Julie Teruya‐Feldstein United States	77	13.1k 1.3×	2.1k 0.3×	7.6k 1.7×	5.5k 1.5×	3.2k 1.1×	216	22.2k

Countries citing papers authored by Craig T. Jordan

Since Specialization

Citations

This map shows the geographic impact of Craig T. Jordan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Craig T. Jordan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Craig T. Jordan more than expected).

Fields of papers citing papers by Craig T. Jordan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Craig T. Jordan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Craig T. Jordan. The network helps show where Craig T. Jordan may publish in the future.

Co-authorship network of co-authors of Craig T. Jordan

This figure shows the co-authorship network connecting the top 25 collaborators of Craig T. Jordan. A scholar is included among the top collaborators of Craig T. Jordan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Craig T. Jordan. Craig T. Jordan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Walker, Zachary J., et al.. (2024). MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance. Clinical Cancer Research. 30(14). 3023–3035. 4 indexed citations

Winters, Amanda, Mohd Minhajuddin, Brett M. Stevens, et al.. (2023). Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine. Haematologica. 109(6). 1766–1778. 5 indexed citations

Culp‐Hill, Rachel, Brett M. Stevens, Courtney L. Jones, et al.. (2023). Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax + Azacitidine by Targeting Fatty Acid Desaturases 1 and 2. Metabolites. 13(4). 467–467. 12 indexed citations

Walker, Zachary J., Brett M. Stevens, Andrew Hammes, et al.. (2020). Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy. Clinical Cancer Research. 27(3). 819–830. 9 indexed citations

Ye, Haobin, Mohammad Minhajuddin, Anna Krug, et al.. (2020). The Hepatic Microenvironment Uniquely Protects Leukemia Cells through Induction of Growth and Survival Pathways Mediated by LIPG. Cancer Discovery. 11(2). 500–519. 19 indexed citations

Gregory, Mark A., Travis Nemkov, Hae J. Park, et al.. (2019). Targeting Glutamine Metabolism and Redox State for Leukemia Therapy. Clinical Cancer Research. 25(13). 4079–4090. 127 indexed citations

Jones, Courtney L., Brett M. Stevens, Angelo D’Alessandro, et al.. (2019). Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. Blood. 134(4). 389–394. 103 indexed citations

Pollyea, Daniel A., Brett M. Stevens, Courtney L. Jones, et al.. (2018). Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nature Medicine. 24(12). 1859–1866. 481 indexed citations breakdown →

Pollyea, Daniel A., Courtney L. Jones, Brett M. Stevens, et al.. (2018). Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1. Blood. 132(Supplement 1). 432–432. 5 indexed citations

10.

Snedeker, Jonathan C., Dmitry Baturin, Susan Fosmire, et al.. (2017). A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia. Molecular Cancer Therapeutics. 16(10). 2058–2068. 55 indexed citations

11.

Zhang, Wei, Brett M. Stevens, Elizabeth Budde, et al.. (2017). Anti-CD123 CAR T-Cell Therapy for the Treatment of Myelodysplastic Syndrome. Blood. 130. 1917–1917. 8 indexed citations

12.

Ho, Tzu‐Chieh, Mark W. LaMere, Brett M. Stevens, et al.. (2016). Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood. 128(13). 1671–1678. 166 indexed citations

13.

Pei, Shanshan, Mohammad Minhajuddin, Angelo D’Alessandro, et al.. (2016). Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. Journal of Biological Chemistry. 291(42). 21984–22000. 33 indexed citations

14.

Alvarez‐Calderon, Francesca, Mark A. Gregory, Deborah DeRyckere, et al.. (2014). Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations. Clinical Cancer Research. 21(6). 1360–1372. 56 indexed citations

15.

Gandhi, Ujjawal H., Naveen Kaushal, Shailaja Hegde, et al.. (2014). Selenium Suppresses Leukemia through the Action of Endogenous Eicosanoids. Cancer Research. 74(14). 3890–3901. 21 indexed citations

16.

Guzmán, Mónica L., Neng Yang, Krishan K. Sharma, et al.. (2014). Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia. Molecular Cancer Therapeutics. 13(8). 1979–1990. 45 indexed citations

17.

Neelakantan, Sundar, Shama Nasim, Mónica L. Guzmán, Craig T. Jordan, & Peter A. Crooks. (2009). Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-κB inhibitor, DMAPT (LC-1). Bioorganic & Medicinal Chemistry Letters. 19(15). 4346–4349. 149 indexed citations

18.

Hassane, Duane C., Mónica L. Guzmán, Cheryl A. Corbett, et al.. (2008). Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood. 111(12). 5654–5662. 145 indexed citations

19.

Mendler, Jason H., Jennifer L. Kelly, Susan Voci, et al.. (2008). Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Annals of Oncology. 19(10). 1759–1764. 28 indexed citations

20.

Guzmán, Mónica L., Carol Swiderski, Dianna S. Howard, et al.. (2002). Preferential induction of apoptosis for primary human leukemic stem cells. Proceedings of the National Academy of Sciences. 99(25). 16220–16225. 334 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact